• Kontakt
• So finden Sie uns
• Klinikumseinrichtungen
• Presse

Eine vollständige Übersicht finden Sie in der Forschungsdatenbank.

Aktuelle Publikationen

Schäfer R, Sers C., Nazarenko I. Apoptosis pathway profiling in ovarian cancer. Ovarian Cancer/Book 1, Intech Open Access Publisher; ISBN 978-953-307-812-0; 2011, accepted

Kaufmann L, Marinescu G, Nazarenko I, Thiele W, Oberle C, Sleeman J, Blattner C. LiCl induces TNF-? and FasL production, thereby stimulating apoptosis in cancer cells, Cell Commun Signal. 2011 May 24;9:15.

Sleeman J, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int. J. Cancer. 2011 Jun 1;128(11):2511-26. (IF 4.72)

Rana S, Claas C, Kretz CC, Nazarenko I, Zoeller M. Activation-induced internalization differs for the tetraspanins CD9 and Tspan8: Impact on tumor cell motilityInt] Int J Biochem Cell Biol. 2011 Jan;43(1):106-19. (IF 4.89)

Nazarenko I*, Jenny M, Keil J,Gieseler C, Weisshaupt K, Sehouli J, Legewie S, Herbst L, Weichert W, Darb-Esfahani S, Dietel M, Schafer R, Ueberall F, Sers C. Atypical PKCzeta exhibits a proapoptotic function in ovarian cancer. Mol Cancer Res. 2010 Jun; 8(6):919-34 (IF 5.20). (*Corresponding Author)

Nazarenko I*, Rana S, Baumann A., McAlear J., Hellwig A, Trendelenburg M, Lochnit G., Preissner KT., Zöller M*. Cell Surface Tetraspanin Tspan8 Contributes to Molecular Pathways of Exosome-Induced Endothelial Cell Activation. Cancer Res. 2010 Feb 15;70(4):1668-78. (IF 7.98) (*Corresponding Authors)

Marhaba R*, Nazarenko I*, Knoefler D, Reich E, Voronov E, Vitacolonna M, Hilderbrand D, Elter E, Apte R, Zoller M. Opposing effects of fibrosarcoma cell-derived IL-1 alpha and IL-1 beta on immune response induction. Int J Cancer. 2008 Jul 1;123(1):134-45. (* Authors with equal contribution) (IF 4.66)

Nazarenko I*, Marhaba R*, Reich E, Voronov E, Vitacolonna M, Hildebrand D, Elter E, Rajasagi M, Apte RN, Zoller M. Neoplasia. Tumorigenicity of IL-1alpha- and IL-1beta-deficient fibrosarcoma cells. 2008 Jun;10(6):549-62. (* Authors with equal contribution) (IF 5.19)

Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller. CD44 and EpCAM: Cancer-Initiating Cell Markers. M. Curr Mol Med. 2008 Dec;8(8):784-804. (IF 4.64)

Fries F, Nazarenko I, Hess J, Claas A, Angel P, Zoller M. CEBPbeta, JunD and c-Jun contribute to the transcriptional activation of the metastasis-associated C4.4A gene. Int J Cancer. 2007 May 15;120 (10):2135-47. (IF 4.66)

Nazarenko I, Schafer R, Sers C. Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells. J Cell Sci. 2007 Apr 15;120(Pt 8):1393-404. (IF 6.25)

Gericke A, Martinka P, Nazarenko I, Persson PB, Patzak Impact of {alpha}1-adrenoceptor expression on contractile properties of vascular smooth muscle cells A. Am J Physiol Regul Integr Comp Physiol. 2007 Jun 6. (IF 3.27)

Waiczies S, Bendix I, Prozorovski T, Ratner M, Nazarenko I, Pfueller CF, Brandt AU, Herz J, Brocke S, Ullrich O, Zipp F. Geranylgeranylation but not GTP-loading determines Rho migratory-function in T cells. J Immunol. 2007 Nov 1;179(9):6024-32 (IF 6.17)

Nazarenko I, Kristiansen G, Fonfara S, Guenther R, Gieseler C, Kemmner W, Schafer R, Petersen I, Sers C. H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling. Am J Pathol. 2006 Oct;169(4):1427-39. (IF 6.2)

Lotz K, Kellner T, Heitmann M, Nazarenko I, Noske A, Malek A, Gontarewicz A, Schafer R, Sers C. Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms. Int J Cancer. 2005 Oct 10;116(6):894-902. (IF 4.66)

Sers C, Husmann K, Nazarenko I, Reich S, Wiechen K, Zhumabayeva B, Adhikari P, Schroder K, Gontarewicz A, Schafer R. Oncogene. The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. 2002 Apr 25;21(18):2829-39. (IF 7.22)

• english